Showing results (351-360 of 1,750) with videos related to
Sort By:
Pageof 175
Journal of Immunotherapy (Hagerstown, Md. : 1997)|November 7, 2019
An IgG1 Version of the Anti-transferrin Receptor 1 Antibody ch128.1 Shows Significant Antitumor Activity Against Different Xenograft Models of Multiple Myeloma: A Brief CommunicationTracy R Daniels-Wells, Pierre V Candelaria, Lai Sum Leoh, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 22, 2020
Pembrolizumab Treatment and Pathologic Therapeutic Evaluation for Granulocyte Colony-stimulating Factor-producing Bladder Cancer: A Case Report and Literature ReviewYuka Muramatsu-Maekawa, Tomoki Taniguchi, Hiroki Ito, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|January 9, 2018
Bullous Pemphigoid-like Skin Lesions and Overt Eosinophilia in a Patient With Melanoma Treated With Nivolumab: Case Report and Review of the LiteratureAmalia Anastasopoulou, Georgios Papaxoinis, Panagiotis Diamantopoulos, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 16, 2022
Pembrolizumab-induced Myasthenia Gravis: Literature Review of Ocular Manifestations and a Refractory CaseOliver Dugena, Chaolan Zheng, Jennifer Taylor, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 27, 2022
Identification of a Germline Pyrin Variant in a Metastatic Melanoma Patient With Multiple Spontaneous Regressions and Immune-related Adverse EventsCameron J Oswalt, Rami N Al-Rohil, Bala Theivanthiran, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 11, 2022
Lower Expression of GBP2 Associated With Less Immune Cell Infiltration and Poor Prognosis in Skin Cutaneous Melanoma (SKCM)Shuguang Zhang, Kun Chen, Zhenguo Zhao, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 3, 2021
Pretreatment Eosinophil Counts in Patients With Advanced or Metastatic Urothelial Carcinoma Treated With Anti-PD-1/PD-L1 Checkpoint InhibitorsJose Mauricio Mota, Min Yuen Teo, Karissa Whiting, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 14, 2021
Safety and Clinical Outcomes of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune DiseasesCynthia Yeung, Adi Kartolo, Ryan Holstead, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|January 4, 2020
Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or AcalabrutinibJim S Qin, Timothy G Johnstone, Alex Baturevych, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 16, 2020
Primary Biliary Cirrhosis and Granulomatous Hepatitis After Immune Checkpoint Blockade in Patients With Metastatic Melanoma: Report of 2 Cases and Literature DiscussionCristel Ruini, Carolin Haas, Sebastian Mastnik, et al.Pageof 175